Search Results
Your search for ,twO matches 11980 pages
Showing 3701 - 3750Feasibility Study of Radical Cystectomy vs Intravesical BCG for High-Grade, Non–Muscle Invasive Bladder Cancer
As reported in the Journal of Clinical Oncology by Catto et al, the BRAVO-Feasibility study showed that recruitment of patients with high-grade, non–muscle invasive bladder cancer into a randomized trial comparing radical cystectomy vs intravesical bacillus Calmette-Guérin (BCG) proved difficult,...
Use of a Novel CAR T-Cell Therapy in Pediatric and Adult Patients With Advanced B-Cell ALL
Pooled results of two phase I studies, reported in The Lancet by Benjamin et al, indicate that the genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell product UCART19 is active and has a manageable toxicity profile in pediatric and adult patients with relapsed...
FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
On January 4, U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn, MD, and Director of the FDA’s Center for Biologics Evaluation and Research Peter Marks, MD, PhD, issued the following statement on FDA-authorized dosing schedules for each COVID-19 vaccine. Two different mRNA...
Nivolumab Indication in Small Cell Lung Cancer Withdrawn in U.S. Market
On December 29, Bristol Myers Squibb issued the following statement on nivolumab’s small cell lung cancer (SCLC) indication in the United States. In 2018, nivolumab was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with SCLC whose disease...
Ganglioside Vaccine Plus β-Glucan for Patients With High-Risk Neuroblastoma and Prior Disease Progression
In a single-institution phase II study reported in the Journal of Clinical Oncology, Cheung et al found that a subcutaneous ganglioside G2/G3 vaccine plus oral β-glucan produced antibody responses in patients with high-risk neuroblastoma, with higher anti–GD2-IgG1 titers being associated with...
FDA Issues Emergency Use Authorization for Second COVID-19 Vaccine
On December 18, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the second vaccine for the prevention of COVID-19 caused by SARS-CoV-2. The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the United States for use in...
Addition of First-Line Pembrolizumab to Chemotherapy in Metastatic Triple-Negative Breast Cancer: KEYNOTE-355
As reported in The Lancet by Javier Cortes, MD, and colleagues, the phase III KEYNOTE-355 trial has shown that the addition of pembrolizumab to chemotherapy improved progression-free survival among previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast...
Gemogenovatucel-T Maintenance in Stage III/IV Ovarian Cancer
In the phase IIb VITAL trial reported in The Lancet Oncology, Rocconi et al found that front-line maintenance with the autologous tumor cell vaccine gemogenovatucel-T did not improve recurrence-free survival vs placebo in patients with stage III/IV ovarian cancer in clinical complete response after ...
NIH RADx-rad Grants Support Investigation of Novel COVID-19 Testing and Surveillance Approaches
The National Institutes of Health (NIH) has awarded over $107 million to support new, nontraditional approaches and reimagined uses of existing tools to address gaps in COVID-19 testing and surveillance. The program will also develop platforms that can be deployed in future outbreaks of COVID-19...
Effect of the COVID-19 Pandemic on Lung Cancer Screening
Reporting on how deferred care worsened outcomes for patients with lung cancer when the COVID-19 pandemic first surged in the spring of 2020, Robert M. Van Haren, MD, MSPH, FACS, and colleagues explained that they have identified a framework that could help people with serious health conditions...
Anthony Fauci, MD, Encourages Patients With Cancer to Receive COVID-19 Vaccine
The American Society of Hematology (ASH) President Stephanie Lee, MD, MPH, sat down with Anthony Fauci, MD, Director of the National Institutes of Allergy and Infectious Diseases (NIAID) and medical advisor to President-Elect Joseph Biden, for a virtual fireside chat about COVID-19 and cancer at...
Chronicling a Family’s History of Cancer
Cancer has been an intimate part of Nancy Borowick’s life since her mother, Laurel, was diagnosed with breast cancer in 1997, when Nancy was 12. She began photographing her mother’s journey with the disease after the cancer recurred in 2009 for her final project for the Documentary Photography and ...
Two Leading Institutions Collaborate to Advance Treatment of Smoldering Multiple Myeloma
The Multiple Myeloma Research Foundation (MMRF) and Dana-Farber Cancer Institute have jointly announced a pioneering research collaboration in smoldering myeloma, a precursor disease to multiple myeloma. Combining the strengths of the MMRF, a leader in multiple myeloma data generation, and...
Selected ASH Abstracts on Novel Treatments of Polycythemia Vera
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for polycythemia vera. For full details of these study...
Novel Combination Under Study in First-Line Treatment of Metastatic Melanoma
A first-line regimen combining the novel interleukin-2 (Il-2) agonist bempegaldesleukin (NKTR-214) with nivolumab showed encouraging clinical activity in patients with metastatic melanoma in the phase I/II PIVOT-02 trial, according to a presentation during the 2020 Annual Meeting of the Society for ...
Sexual Health: An Issue for Many Survivors of Cancer
Sexual dysfunction is prevalent among cancer survivors—and rarely addressed—according to data presented during the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 A survey of cancer survivors has found that nearly 9 out of 10 respondents reported some change after cancer...
Novel Radiomodulation Approach With Dismutase Mimetic Plus SBRT in Resectable Pancreatic Cancer
Pancreatic cancer is one of the most aggressive, lethal malignancies, and life-extending treatments represent a critical unmet need. A pilot study suggests a potential way forward for patients with nonmetastatic unresectable or borderline resectable pancreatic cancer may be a combination of...
Pralsetinib for RET-Altered Thyroid Cancers
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 1, 2020, pralsetinib (Gavreto) was granted...
ASH Registry: Treasure Trove of Data on COVID-19 and Hematologic Malignancies
The ASH Research Collaborative COVID-19 Registry for Hematology provides up-to-date information on outcomes and the course of illness for a group of patients with hematologic malignancies and COVID-19.1 In general, registry data showed that hematologic malignancies increase the risk of severity of...
ASH Announces Donation of Next-Generation Sequencing Equipment to Countries in the International Consortium
The American Society of Hematology (ASH) recently announced the donation of next-generation sequencing equipment to six reference laboratories in five countries in Latin America. These countries constitute the International Consortium on Acute Leukemia (ICAL), a clinical network supported by the...
Expert Point of View: Jacob Soumerai, MD
“CAPTIVATE is a very important study,” stated Jacob Soumerai, MD, Associate Professor at Harvard Medical School and Massachusetts General Hospital Cancer Center. “The take-home point is that this [ibrutinib plus venetoclax] is highly effective therapy and achieves a high rate of undetectable...
Ruxolitinib Improves Outcomes in Patients With Steroid-Refractory or Steroid-Dependent Graft-vs-Host Disease
Ruxolitinib was superior to best available therapy in achieving efficacy as determined by best overall response and duration of response, with acceptable safety in adolescents and adults with steroid-dependent or steroid-refractory chronic graft-vs-host disease effects. These findings were shown in ...
Adamantinoma of the Mandible
The text and photographs here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Radium Era 1916–1945 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photographs appear courtesy of Stanley B. Burns, MD, and The Burns...
Germline-Somatic Interactions in Advanced Urothelial Cancer and Their Role in Disease Progression
In a study reported in Nature Communications, Bishoy M. Faltas, MD, of the Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, and colleagues identified common germline-somatic variant interactions in advanced urothelial cancer, with these...
Life and Death Under COVID-19
Victoria was a 79-year-old woman living alone in a London suburb. Having no children of her own, she visited us regularly here in the United States. She was one of three sisters and my sister-in-law. I knew her for more than 50 years, and she always reminded me of Audrey Hepburn, both in looks and ...
Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow
On November 25, 2020, naxitamab-gqgk (Danyelza) was granted accelerated approval for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone...
Initial Therapy for Asymptomatic Follicular Lymphoma: Start With Watch and Wait or Rituximab
For patients with indolent follicular lymphoma, generally take a conservative approach to treatment unless the patient is symptomatic, advised John P. Leonard, MD, Executive Vice-Chair of Weill Department of Medicine at Weill-Cornell Medicine/NewYork-Presbyterian, New York.1 “Prognostic scores are...
RxPONDER: Many Postmenopausal Patients With Node-Positive Breast Cancer Can Avoid Chemotherapy
Just in are the results of the SWOG S1007 RxPONDER trial, which evaluated the benefit of chemotherapy in women with early-stage hormone receptor–positive, HER2-negative breast cancer and node-positive disease.1 The data showed that many postmenopausal women can skip adjuvant chemotherapy, based on ...
2020 FDA Approvals of Drugs for Cancer Treatment
Over the past year (January to December 2020), the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for older therapeutic agents used in oncology and hematology. A brief review of new approvals appears here. For complete prescribing information for ...
Transplant May Improve Survival in Older Patients With High-Risk Myelodysplastic Syndrome, Study Reports
Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN 1102), these patients may indeed achieve a survival benefit from stem cell transplant. As...
Daughter of a Dance Band Leader Becomes Nationally Regarded Expert in Disparities of Cancer Care
Electra D. Paskett, PhD, was born in New York City, the daughter of a Greek immigrant who led a notable dance band. As a young child, Dr. Paskett frequented her parents’ rehearsal and dance studio, which was situated above a bustling Woolworth’s Five-and-Dime store. One of the studio’s famous...
FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma
On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved selinexor (Xpovio) in combination with bortezomib (Velcade) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The FDA granted selinexor accelerated...
FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer
Today, the U.S. Food and Drug Administration (FDA) approved relugolix (Orgovyx) for the treatment of adult patients with advanced prostate cancer. “Today’s approval marks the first oral drug in this class and it may eliminate some patients’ need to visit the clinic for treatments that require...
ESMO Immuno-Oncology 2020: First-Line Anti–PD-1 Therapy vs BRAF/MEK Inhibition for Advanced BRAF V600–Mutated Melanoma
Findings from a propensity-matched survival analysis presented by van Breeschoten et al at the European Society for Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 (Abstract 37P) suggest that patients with advanced melanoma and a BRAF V600 mutation derive an enhanced survival benefit...
Radiotherapy and Chemotherapy Before Total Mesorectal Excision for Locally Advanced Rectal Cancer: Comparison of Regimens
As reported in The Lancet Oncology by Bahadoer et al, the phase III RAPIDO trial has shown improved 3-year disease-related treatment failure with preoperative short-course radiotherapy followed by chemotherapy and total mesorectal excision (TME) vs preoperative chemoradiotherapy, TME, and optional...
Association of Out-of-Pocket Costs for Tyrosine Kinase Inhibitors With Outcomes in Patients With EGFR- and ALK-Positive Advanced NSCLC
In a single-institution study reported in JCO Oncology Practice, Bernardo H.L. Goulart, MD, and colleagues found that higher out-of-pocket costs for tyrosine kinase inhibitors (TKIs) were associated with reduced adherence to and increased discontinuation of TKI therapy—as well as poorer overall...
Study Shows Sentinel Lymph Node Biopsy to Be 'Viable Option' for Surgical Staging of Endometrial Cancer
Sentinel lymph node biopsy “had similar diagnostic accuracy and prognostic ability as lymphadenectomy in patients with high-grade endometrial cancer at greatest risk for nodal metastases,” according to the SENTOR trial, a prospective cohort study of 156 patients with clinical stage I disease. Using ...
Updated Results of CASPIAN Trial: Addition of Durvalumab With or Without Tremelimumab to Chemotherapy in Extensive-Stage SCLC
As reported in The Lancet Oncology by Goldman et al, updated results from the phase III CASPIAN trial showed maintained improvement in overall survival with first-line durvalumab plus platinum/etoposide vs platinum/etoposide in patients with extensive-stage small cell lung cancer (SCLC). However,...
FDA Approves Margetuximab-cmkb Plus Chemotherapy for Previously Treated Patients With Metastatic HER2-Positive Breast Cancer
On December 16, the U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for...
Reducing the Risk of Lymphedema in Patients With Cancer
Although the exact incidence of treatment-related lymphedema among cancer survivors is unknown—most likely due to its prolonged latency period—it can be a lifelong chronic side effect that negatively impacts survivors’ quality of life. Although the condition is often linked to treatment for breast...
ESMO Immuno-Oncology 2020: Tebentafusp Shows Activity in Metastatic Uveal Melanoma
Tebentafusp is a novel bispecific molecule consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target gp100-positive cells. The agent showed clinical benefit, including target lesion reduction, in patients with metastatic uveal melanoma,...
Spectrum of Germline-Somatic Interactions in Advanced Urothelial Cancer
In a study reported in Nature Communications, Vosoughi et al identified common germline-somatic variant interactions in advanced urothelial cancer, with these interactions appearing to play a central role in disease progression. As stated by the investigators, “The prevalence and the biologic...
Eric P. Winer, MD, FASCO, Elected ASCO President for 2022–2023 Term
ASCO has elected Eric P. Winer, MD, FASCO, a longtime member and volunteer, to serve as its President for the term beginning in June 2022. He will take office as President-Elect during the ASCO Annual Meeting in June 2021. Five new members were also elected to the ASCO Board of Directors and the...
Meta-analysis of Radiotherapy With Adjuvant vs Neoadjuvant Androgen-Deprivation Therapy for Localized Prostate Cancer
In an individual patient meta-analysis reported in the Journal of Clinical Oncology, Daniel E. Spratt, MD, and colleagues found that adjuvant androgen-deprivation therapy (ADT) was associated with improved progression free-survival vs neoadjuvant ADT in patients receiving radiotherapy for localized ...
Postoperative Cancer Surgery Mortality Rates Have Improved, but Gap Still Exists Between Black and White Patients
Mortality rates after cancer surgery declined for Black as well as White patients during a recent 10-year period, although the mortality gap between the two groups did not narrow, according to new research published by Miranda Lam, MD, MBA, and colleagues in JAMA Network Open. The findings present...
FDA Issues Emergency Use Authorization for First COVID-19 Vaccine
On December 11, the U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for a vaccine for the prevention of COVID-19 caused by SARS-CoV-2 in individuals aged 16 and older. The EUA allows the Pfizer-BioNTech COVID-19 vaccine to be distributed in the United...
ASH 2020: Phase II ZUMA-12 Study Investigates Axicabtagene Ciloleucel for High-Risk Large B-Cell Lymphoma
The phase II ZUMA-12 trial found that axicabtagene ciloleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is a safe and effective therapy for patients with high-risk large B-cell lymphoma. These results were presented by Sattva S. Neelapu, MD, and colleagues at the 2020 ...
SABCS 2020: Can Mindfulness Meditation and Survivorship Education Help to Reduce Depression in Young Breast Cancer Survivors?
New research showed that behavioral interventions—mindfulness meditation and survivorship education classes—may be effective in reducing depressive symptoms in younger breast cancer survivors. This patient population often experiences the highest levels of depression, stress, and fatigue, which may ...
New Rules on Health-Care Price Transparency and Coverage for COVID-19 Vaccines
ON OCTOBER 28, the U.S. Department of Health and Human Services (HHS), the U.S. Department of Labor, and the U.S. Department of the Treasury released the coverage transparency final rule. Building on earlier administration actions requiring hospitals to disclose standard charges and negotiated...
Albert Einstein College of Medicine Researchers Receive $5 Million Grant From the National Institutes of Health
A TEAM OF SCIENTISTS from Albert Einstein College of Medicine has received a 5-year, $4.9 million grant from the National Institutes of Health (NIH) to establish a research center to investigate human immunodeficiency virus (HIV)- and human papillomavirus (HPV)-related cancers in Africa. The...
